Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 20th, 2026

Drug-Device Combination Apps: The FDA's 3 Questions for Sponsors

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

Ravulizumab gains FDA accelerated approval for IgA nephropathy after it cut proteinuria by 43.4%.

October 22nd, 2026

Ravulizumab's IgA Nephropathy Approval Expands Large-Molecule Biologic Demand

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.

October 21st, 2026

AAPS PharmSci 360 2026: E&L Standards Harmonization

Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.

Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.

October 21st, 2026

Nitrosamine Problems and Industry Solutions: PharmTech Explained

Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.

October 20th, 2026

AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing

Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.

Roche, Merck KGaA, and Lilly deals in ADCs, siRNA, and lipid nanoparticles reshape drug production.

October 19th, 2026

Three Targeted Delivery Deals: What CMC Teams Should Watch

Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.

October 19th, 2026

Expedited IND Pilot Targets Sequential Delays Slowing First-in-Human Trials

Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.

Generic Drug Battles Heat Up

Articles in this issue

Related to this article

Trending on Pharmaceutical Technology

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing

Nitrosamine Problems and Industry Solutions: PharmTech Explained

Germany’s Medical Biotechnology Sector is Flourishing